4.6 Review

The roles of interleukin-1 receptor accessory protein in certain inflammatory conditions

期刊

IMMUNOLOGY
卷 166, 期 1, 页码 38-46

出版社

WILEY
DOI: 10.1111/imm.13462

关键词

IL-1; IL-1 receptor accessory protein; Inflammation

资金

  1. Iran University of Medical Sciences [18920]

向作者/读者索取更多资源

This review discusses the role of IL-1RAcP in the pathogenesis of different inflammatory diseases, including autoimmunity, obesity, and psoriasis. Aberrant signaling of IL-1RAcP plays a central role in the development of these chronic inflammatory diseases. The IL-1RAcP signaling pathway is also considered a potential therapeutic target.
Interleukin-1 receptor accessory protein (IL-1RAcP) is a member of the immunoglobulin superfamily proteins consisting of soluble and membranous isoforms. IL-1RAcP plays an essential role in the signaling of the IL-1 family cytokines such as IL-1, IL-33 and IL-36, as well as tyrosine kinases FLT3 and C-Kit. IL-1RAcP generally initiates inflammatory signaling pathway through the recruitment of signaling mediators, including MYD88 and IRAK. Chronic inflammation following prolonged signaling of cytokine receptors is a critical process in the pathogenesis of many inflammatory disorders, including autoimmunity, obesity, psoriasis, type 1 diabetes, endometriosis, preeclampsia and Alzheimer's disease. Recently IL-1RAcP aberrant signaling has been considered to play a central role in the pathogenesis of these chronic inflammatory diseases. Targeting IL-1RAcP signaling pathway that was recently considered in clinical trials related to malignancies also indicates its potential as therapeutic target for the inflammatory and autoimmune diseases. This review summarizes the molecular structure, components associated with IL-1RAcP signaling pathways, and their involvement in the pathogenesis of different inflammatory diseases. We will also discuss the effect of IL-1RAcP inhibition for treatment proposes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据